Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 4/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1118036 | 0.92 | HCAR3 (0.36) | HCAR3NPC1ALDH1A1TP53POLB | |
| SCHEMBL1783498 | 0.89 | HCAR3 (0.43) | HCAR3NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1117865 | 0.88 | HCAR3 (0.42) | HCAR3NPC1ALDH1A1TP53POLB | |
| SCHEMBL1117949 | 0.87 | OGA (0.33) | NPC1ALDH1A1TP53POLBRAB9A | |
| SCHEMBL1117941 | 0.87 | HCAR3 (0.41) | HCAR3NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1117883 | 0.87 | HCAR3 (0.41) | HCAR3NPC1ALDH1A1TP53POLB | |
| SCHEMBL1780133 | 0.85 | HCAR3 (0.39) | HCAR3NPC1ALDH1A1TP53POLB | |
| SCHEMBL27857536 | 0.85 | HCAR3 (0.39) | HCAR3NPC1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL1783367 | 0.82 | HCAR3 (0.37) | HCAR3NPC1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL1117984 | 0.82 | HCAR3 (0.40) | HCAR3ALDH1A1POLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8304556-B2 | Thiazolyl-dihydro-indazoles | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-11-06 | — | — | US | disclosed |
| US-8304556-B2 | Thiazolyl-dihydro-indazoles | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-11-06 | — | — | US | disclosed |
| US-20120108567-A1 | Thiazolyl-Dihydro-Indazoles | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-03 | — | — | US | disclosed |
| US-20120108567-A1 | Thiazolyl-Dihydro-Indazoles | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-03 | — | — | US | disclosed |
| US-20110118208-A1 | Thiazolyl-Dihydro-Indazoles | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-05-19 | — | — | US | disclosed |
| EP-2280982-A1 | THIAZOLYL-DIHYDRO-INDAZOLES | Boehringer Ingelheim International GmbH (DE) | 2011-02-09 | — | — | EP | disclosed |
| WO-2009112565-A1 | THIAZOLYL-DIHYDRO-INDAZOLES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-17 | — | — | WO | disclosed |
| WO-2009112565-A1 | THIAZOLYL-DIHYDRO-INDAZOLES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108567-A1 | Thiazolyl-Dihydro-Indazoles | MKI67, CYP11B1, IGF1R | HCAR3 2774/4885NPC1 136/4885ALDH1A1 54/4885 |
| US-20110118208-A1 | Thiazolyl-Dihydro-Indazoles | MKI67, CYP11B1, IGF1R | HCAR3 2774/4885NPC1 136/4885ALDH1A1 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.